UK Turbulence Not Expected To Disrupt Supply
No ‘Major Disruption’ Anticipated Despite Brexit Cliff And Freight Restrictions
Despite Brexit uncertainty and travel restrictions that have just been imposed on the UK, the country’s generics industry is not expected to suffer major disruptions.
You may also be interested in...
Guidance from the UK’s MHRA on post-Brexit arrangements relevant to the off-patent industry has been welcomed by local industry body the BGMA. However, it has warned that time is short to prepare for the end of the UK-EU transition period, with new guidance in certain areas “critical.”
While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.